Table 4.
Risk of All Cause Mortality Based on Clinical Factors at Randomization and the Time of PSA Recurrence for 89 Men Who Experienced PSA Recurrence
| Clinical Factor | Adjusted HR | 95% CI | P |
|---|---|---|---|
| Age, years (at time of PSA failure, continuous) | 1.01 | 0.93 to 1.10 | .81 |
| Treatment arm | |||
| RT and AST | 1.00 | — | |
| RT alone | 2.09 | 0.74 to 5.92 | .16 |
| Log PSA | 1.08 | 0.59 to 1.98 | .80 |
| Gleason score | |||
| ≤ 6 | 1.00 | — | |
| 7 | 1.26 | 0.42 to 3.75 | .68 |
| 8-10 | 2.67 | 0.78 to 9.17 | .12 |
| Tumor category | |||
| T1 | 1.00 | — | |
| T2 | 1.15 | 0.50 to 2.65 | .74 |
| ACE-27 comorbidity score | |||
| No or minimal | 1.00 | ||
| Moderate or severe | 7.94 | 1.55 to 40.52 | .01 |
| Treatment arm comorbidity* | 0.17 | 0.02 to 1.31 | .09 |
| Time to PSA failure (continuous) | 1.21 | 0.89 to 1.65 | .22 |
| PSA velocity (continuous) | 1.60 | 1.23 to 2.09 | < .001 |
| Time-dependent salvage AST | 1.09 | 0.79 to 1.49 | .60 |
Abbreviations: PSA, prostate-specific antigen; HR, hazard ratio; RT, radiation therapy; AST, androgen suppression therapy; ACE-27, Adult Comorbidity Evaluation 27.
*
Interaction term.